A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
about
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.Profile of selumetinib and its potential in the treatment of melanoma.The biology and clinical development of MEK inhibitors for cancer.Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from ten Phase I trials.Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.Selumetinib in the treatment of non-small-cell lung cancer.Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, SelumetinibA phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
P2860
Q33439877-CB49A169-CF6F-43E4-8FEA-0FD5A9BEBFB3Q33626185-B3D2FB22-EC79-4231-A421-7E505C3B9645Q33729778-2A8CC969-B823-4824-8DF1-7035228C8231Q35677661-84B16517-A76C-42E8-9676-4C43BC162E00Q37580873-6F4B0A21-7873-4550-A774-04B2A03C256BQ37990969-1FA55BCE-D630-4D8E-80A8-856700236B06Q38256348-A8958007-3299-4D8D-84F7-61CC69117611Q38270129-DB1F4EFA-B4F6-446E-9C90-7DE1AF09C9DCQ38612177-C549555A-ED06-41E8-87E4-EEE2BDF21E9DQ38798084-1E8882BD-1BCD-4C56-B5A8-55D3DD10CFD8Q38836927-EF1A3DB2-BFE9-46CF-804C-51B64A878EE7Q39466460-E6073B1F-16B8-476D-827A-6B59769CBE0AQ41697013-DC7559DA-720F-4360-9F94-D1A747011595Q42363767-1482D29C-5C33-443A-B7D6-23A890538236
P2860
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A phase I, open-label, randomi ...... nts with advanced solid tumors
@ast
A phase I, open-label, randomi ...... nts with advanced solid tumors
@en
type
label
A phase I, open-label, randomi ...... nts with advanced solid tumors
@ast
A phase I, open-label, randomi ...... nts with advanced solid tumors
@en
prefLabel
A phase I, open-label, randomi ...... nts with advanced solid tumors
@ast
A phase I, open-label, randomi ...... nts with advanced solid tumors
@en
P2093
P2860
P1476
A phase I, open-label, randomi ...... nts with advanced solid tumors
@en
P2093
Jan H M Schellens
Lynda Grinsted
Maria Learoyd
Marianne Nicolson
Mark Middleton
Patricia M M B Soetekouw
Suzanne Leijen
T R Jeffry Evans
Thinn Pwint
Victoria Zazulina
P2860
P2888
P304
P356
10.1007/S00280-011-1732-7
P577
2011-09-28T00:00:00Z